RNF185 antisense RNA 1 (RNF185-AS1) promotes proliferation, migration, and invasion in papillary thyroid carcinoma

Abstract

Long noncoding RNA (lncRNA) plays an important role in multiple cancers. So far, the exact function of lncRNAs in papillary thyroid carcinoma (PTC) is unclear. The purposes of this work were to investigate the function and underlying mechanisms of RNF185 antisense RNA 1 (RNF185-AS1) in PTC. The expression of RNF185-AS1 was analyzed by quantitative real-time PCR (qRT-PCR). Colony formation, 5-ethynyl-2′-deoxyuridine, and Cell Counting Kit-8 assays were utilized to determine cell proliferation. Cell migration and invasion were tested using wound healing and transwell assays. A mouse transplantation tumor model was used for tumor growth analyses in vivo. The regulation of RNF185-AS1 on the downstream miR-429/lipoprotein receptor-related protein (LRP4) axis was predicted and identified through bioinformatic analysis, dual-luciferase reporter assay, and RNA immunoprecipitation (RIP) assay. RNF185-AS1 was dramatically overexpressed in PTC tumors and cells. High RNF185-AS1 expression was associated with bigger tumor size, lymph node metastasis, and advanced tumor-node-metastasis stage in PTC patients. Silencing of RNF185-AS1 impeded the proliferation, migration, and invasion in vitro and constrained tumorigenesis in vivo. Mechanistically, RNF185-AS1 could act as a sponge of miR-429 to regulate the expression of LRP4. In addition, downregulation of miR-429 or upregulation of LRP4 could relieve the proliferation, migration, and invasion of IHH-4 and TPC-1 cells that inhibited by RNF185-AS1 knockdown. Downregulation of RNF185-AS1 may suppress PTC progression through functioning as a sponge of miR-429 to hinder the expression of LRP4. The RNF185-AS1/miR-429/LRP4 axis will lay the groundwork for future therapeutic strategies in PTC.

Predictors based on cuproptosis closely related to angiogenesis predict colorectal cancer recurrence

“…Relevant research indicates that DLEU1 , as a protective predictor, is a candidate gene of tumor suppressor involved in B-cell chronic lymphocytic leukemia ( 38 ). RNF185-AS1 , in contrast, has the effect of promoting proliferation and migration in thyroid carcinoma and liver cancer ( 39 , 40 ). The effect of the two predictors in tumor progression confirmed their influence on the prediction of survival probability.…”

Role of the Mitochondrial E3 Ubiquitin Ligases as Possible Therapeutic Targets in Cancer Therapy

“…RNF185-AS1 silencing has been found capable of impeding the proliferation, migration and invasion of the cancer cells in vitro and to reduce tumorigenesis in vivo. Thus, the RNF185-AS1/miR-429/LRP4 axis may represent a potential target for the development of therapeutic strategies in PTC [44]. Downregulation of RNF185 expression has been found to correlate with prostate cancer progression and metastasis, and when RNF185 is reduced, the wound healing and cellular movement pathways were the most significant that were found upregulated.…”